Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23272146 | 0.94 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20242214 | 0.90 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15643263 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29259975 | 0.87 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21227696 | 0.87 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30938298 | 0.87 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25565728 | 0.87 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1964279 | 0.86 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21759713 | 0.86 | DDB1 (0.66) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26317539 | 0.85 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203176-A2 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS | Celgene Cellular Therapeutics (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009045360-A2 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS | CELGENE CELLULAR THERAPEUTICS (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1974013-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | Anthrogenesis Corporation (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1901789-A2 | REPAIR OF TYMPANIC MEMBRANE USING PLACENTA DERIVED COLLAGEN BIOFABRIC | Anthrogenesis Corporation (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007079185-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007005807-A2 | REPAIR OF TYMPANIC MEMBRANE USING PLACENTA DERIVED COLLAGEN BIOFABRIC | ANTHROGENESIS CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1694328-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND MANAGEMENT OF HEMOGLOBINOPATHY AND ANEMIA | CELGENE CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005055929-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND MANAGEMENT OF HEMOGLOBINOPATHY AND ANEMIA | CELGENE CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |